Neurologic Diseases and Neurogenetics

Biomarkers in neurological disease: ALS, MS, Alzheimer's Disease...
New therapeutic strategies in Neurological Diseases
Epidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
Lexical access disorders in speech production
Prothrombotic mechanisms in patients with Stroke
Neurophysiological markers in postanoxic patients
Neuronal networks and Epilepsy
Personalized and Precision Medicine in neurological disease
Prognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia...

- Munoz Vendrell A, Sala Padro J, Jaraba S, Reynes Llompart G, Veciana M, Mora J, Falip M. Functional neuroimaging in nonepileptiform electroencephalographic patterns in status epilepticus. Acta Neurol. Scand. 2021;144(6):687-694. doi:10.1111/ane.13515. IF:3,21.

- Gifreu A, Falip M, Sala Padro J, Mongay N, Morandeira F, Camins A, Naval Baudin P, Veciana M, Fernandez M, Pedro J, Garcia B, Arroyo P, Simo M. Risk of Developing Epilepsy after Autoimmune Encephalitis. Brain Sci. 2021;11(9):doi:10.3390/brainsci11091182. IF:3,39.

- Andres Benito P, Gelpi E, Jove M, Mota Martorell N, Obis E, Portero Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol. Appl. Neurobiol. 2021;47(4):544-563. doi:10.1111/nan.12681. IF:8,09.

- Alemany M, Nunez A, Falip M, Lara B, Paipa A, Quesada H, Mora P, de Miquel MA, Barranco R, Pedro J, Cardona P. Acute symptomatic seizures and epilepsy after mechanical thrombectomy. A prospective long-term follow-up study. SEIZURE-EUR J EPILEP. 2021;895-9. doi:10.1016/j.seizure.2021.04.011. IF:3,18.

- Andrés Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging-US. 2021;13(20):23871-23871. doi:10.18632/aging.203667. IF:5,68.

- 18PSJ028. Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis. (HR17-00777). FUNDACIÓ "LA CAIXA"; FUNDACIO IDIBELL; FUNDACION MANUEL PEREZ (FMP); UNIV. AUTONOMA BARCELONA. 2018-2022. IP:POVEDANO PANADES,MONICA.

- 18MAR003. ADDRESSING CHALLENGES OF STROKE CARE IN THE XXIst CENTURY: REACHING REPERFUSION THERAPY TOP RATES, ELIMINATING INEQUALITIES IN ACCESS AND DEALING WITH BIG DATA. (201712-32). BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (BSC-CNS); FUNDACIÓ ICTUS; FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,ANTONIO.

- 18MAR002. The Chemical Optimization of Cerebral Embolectomy (CHOICE) Trial. (201707-31). FUND. CLINIC PER RECERCA BIOMEDICA; FUNDACIO IDIBELL; FUNDACIÓ IMIM; FUNDACIÓ INSTITUT DE RECERCA VALL D’HEBRON; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,SERGIO.

- ACL:2022-010-1. A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). (CY5031). CYTOKINETICS, INC. 2021IP:MONICA POVEDANO PANADES.

- ACL:2021-080-1. ESTUDIO DE FASE III DE NO INFERIORIDAD, ALEATORIZADO, ABIERTO, DE GRUPOS PARALELOS Y MULTICÉNTRICO PARA INVESTIGAR LA FARMACOCINÉTICA, LA FARMACODINÁMICA, LA SEGURIDAD Y LOS EFECTOS RADIOLÓGICOS Y CLÍNICOS DE OCRELIZUMAB SUBCUTÁNEO EN COMPARACIÓN CON OCRELIZUMAB INTRAVENOSO EN PACIENTES CON ESCLEROSIS MÚLTIPLE. (CN42097). ROCHE FARMA S.A. 2021IP:SERGIO MARTINEZ YELAMOS.

PROJECTS

• Title: Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis
• PI: Povedano Padanes, Mònica
• Coordinator: Universitat Autònoma de Barcelona- UAB (Project Leader: Dr. Rubèn López Vales)
• Call reference: Health Research 2017 Call for proposals, expediente: HR17-00777
• Funder: Fundació “la Caixa”